- Home
- MIY vs CDXS Comparison
MIY vs CDXS Comparison
Compare MIY & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIY
- CDXS
- Stock Information
- Founded
- MIY 1992
- CDXS 2002
- Country
- MIY United States
- CDXS United States
- Employees
- MIY N/A
- CDXS N/A
- Industry
- MIY Investment Bankers/Brokers/Service
- CDXS Major Chemicals
- Sector
- MIY Finance
- CDXS Industrials
- Exchange
- MIY Nasdaq
- CDXS Nasdaq
- Market Cap
- MIY 340.0M
- CDXS 332.0M
- IPO Year
- MIY N/A
- CDXS 2010
- Fundamental
- Price
- MIY $11.64
- CDXS $4.02
- Analyst Decision
- MIY
- CDXS Buy
- Analyst Count
- MIY 0
- CDXS 3
- Target Price
- MIY N/A
- CDXS $10.50
- AVG Volume (30 Days)
- MIY 56.8K
- CDXS 549.5K
- Earning Date
- MIY 01-01-0001
- CDXS 10-31-2024
- Dividend Yield
- MIY 3.98%
- CDXS N/A
- EPS Growth
- MIY N/A
- CDXS N/A
- EPS
- MIY N/A
- CDXS N/A
- Revenue
- MIY N/A
- CDXS $64,446,000.00
- Revenue This Year
- MIY N/A
- CDXS N/A
- Revenue Next Year
- MIY N/A
- CDXS $2.02
- P/E Ratio
- MIY N/A
- CDXS N/A
- Revenue Growth
- MIY N/A
- CDXS N/A
- 52 Week Low
- MIY $9.45
- CDXS $1.72
- 52 Week High
- MIY $11.70
- CDXS $4.91
- Technical
- Relative Strength Index (RSI)
- MIY 44.21
- CDXS 67.75
- Support Level
- MIY $11.52
- CDXS $3.08
- Resistance Level
- MIY $11.78
- CDXS $4.39
- Average True Range (ATR)
- MIY 0.09
- CDXS 0.24
- MACD
- MIY 0.01
- CDXS 0.08
- Stochastic Oscillator
- MIY 50.00
- CDXS 75.17
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from federal and Michigan income taxes.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.